What Does Viatris’ Trio Of Attacks On US Semaglutide Mean For Wegovy Generics?

Viatris’ Spate Of Inter Partes Reviews Largely Denied, With One Upside For Firm

05 Oct 2023

Viatris has failed in its attempt to begin proceedings to overturn two key semaglutide patents in the US, while succeeding on another, as part of its bid to gain early entry with its proposed generic version of Novo Nordisk’s renowned Wegovy. Generics Bulletin reviews the landscape.

A US patent tribunal office has refused Viatris’ requests to invalidate two US semaglutide composition patents, the active ingredient in Novo Nordisk’s renowned Wegovy treatment for obesity among other of the Danish originator’s major brands, raising the potential for generic competition to be pushed out until the early 2030s.

In two separate petitions, Viatris had requested the US Patent and Trademark Office’s Patent Trial Appeal Board to institute an...